The Liquidity Paradox of the 505(b)(2) Drug Development Pathway
In a recent article published in Cell Press Trends in Biotechnology, Managing Partner Oded Ben-Joseph, PhD, MBA and Managing Director Stanislav Glezer, MD, MBA examine why more efficient development does not always translate into stronger or earlier liquidity outcomes, and explore possible solutions to overcome this challenge.
Outcome Capital highlights a critical dynamic shaping biopharma investment strategy: the liquidity paradox of the 505(b)(2) pathway.
Published in Trends in Biotechnology
Authors: Oded Ben-Joseph, Stanislav Glezer
Abstract:
In a recent article published in Trends in Biotechnology, Managing Partner Oded Ben-Joseph, PhD, MBA and Managing Director Stanislav Glezer, MD, MBA examine why more efficient development does not always translate into stronger or earlier liquidity outcomes, and explore possible solutions to overcome this challenge.
News
ProjectMedtech Podcast | Strategic Transactions in MedTech: Insights & Advice
Recent podcast conversation featuring Stanislav Glezer, Managing Director at Outcome Capital, on the ProjectMedtech Podcast, hosted by Duane Mancini.
Read MoreResources
Outcome Capital Life Science Market Pulse
Outcome Capital Life Science Market Pulse February 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
